Business Wire

BEARINGPOINT

12.9.2019 09:22:09 CEST | Business Wire | Press release

Share
BearingPoint: 10 years of success, ready for the next decade

Almost ten years to the day after the management buyout (MBO) that established the independent, Partner-led management and technology consultancy in 2009, BearingPoint announced that it has launched its Strategy 2025 for even greater success in the decade ahead. Three major ambitions drive the Strategy 2025: to put people in the center, to outperform the market every year and enable European clients to become global leaders, and to be within the top three players in key areas of expertise. Cornerstones of the strategy are to focus on five key areas in consulting for a clear differentiation in the market, to generate new revenue streams with intellectual property, to build critical mass within all practices, to accelerate the growth of BearingPoint’s solutions business, to foster greater collaboration between communities for more innovation, to leverage new business models and ecosystems, and to recruit, develop and retain the best talent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005072/en/

“It’s our firm’s 10th anniversary since we executed our management buyout back in 2009 and created the independent BearingPoint partnership, which I am proud to be part of today. Our Strategy 2025 builds on our existing strengths and puts people first. It outlines clear ambitions for the years ahead and focuses our business and differentiates us in the market,” said Kiumars Hamidian, Managing Partner of BearingPoint. “We are a European success story because of our strong client relationships, our intellectual property, and our people culture, and I am confident that our Strategy 2025 will keep the success going for us and our clients.”

BearingPoint had record revenues of €738 million in 2018 and has grown to more than 4,500 people. The firm said its Strategy 2025 is closely aligned to the market so that growth remains steady and profitable.

Strategy: Focus & Differentiate
BearingPoint said it is building on and further expanding the strengths that differentiate it: the firm’s culture and principles, its management and technology capabilities, its ability to create IP within ecosystems, and its independence and European roots.

“IP creation is something that we already have in our DNA,” said Kiumars, “and we will emphasize this much more. We want to make sure that the great work done on projects is leveraged across the firm from everyone at BearingPoint. Our people-centric approach is characterized by collaboration and communication and reflected in three dimensions: our clients, where we want to focus on the people aspect behind business transformation; our people, where we want to ensure that BearingPoint is the best place to develop and grow; and the communities around us, where we want to make a positive impact.”

BearingPoint structured its operating model into three units. The first unit covers the consulting business with a clear focus on key areas to drive growth across all regions. Earlier this year, BearingPoint established Business Services as a second unit in which it provides IP-driven managed services beyond SaaS and offers business critical services to support the business success of clients. The third business unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.

To create synergies, BearingPoint also combined its practices into three regions: FBLA (France, Belgium, Luxembourg, Africa) led by Eric Falque, GSA (Germany, Switzerland, Austria) led by Iris Grewe, and GROW (Ireland, United Kingdom, Italy, Sweden, Finland, Norway, Netherlands) led by James Rodger. The firm said it seeks to have critical mass in all its practices, which means having at least 100 people in each practice.

The new operating model took effect on September 1.

Management Changes
Matthias Loebich will lead the Markets area of the Consulting unit that comprises all its industry segments. Damien Palacci is leading the Consulting Portfolio, which helps functions of companies with innovative offerings. Patrick Palmgren will lead the newly created business unit covering solutions, M&A activities, and ventures.

Donald Wachs, who leads the Business Services unit, and Damien Palacci have joined the Management Committee of BearingPoint.

About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 75 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com
Annual Report: www.bearingpoint.com/en/about-us/annual-report/
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye